Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
Titel:
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
Auteur:
Sehouli, J. Chekerov, R. Reinthaller, A. Richter, R. Gonzalez-Martin, A. Harter, P. Woopen, H. Petru, E. Hanker, L.C. Keil, E. Wimberger, P. Klare, P. Kurzeder, C. Hilpert, F. Belau, A.K. Zeimet, A. Bover-Barcelo, I. Canzler, U. Mahner, S. Meier, W.